BrainStorm Cell Therapeutics, Inc. (BCLI) to Commence Multiple Sclerosis Study at Hadassah Medical Center
BrainStorm Cell Therapeutics, a biotech company engaged in the development adult stem cell technologies for neurodegenerative diseases, reports that it will initiate a pre-clinical study for multiple sclerosis (MS) at the Hebrew University Hadassah Medical Center’s SPF-grade animal laboratory in Jerusalem. Based on favorable pre-clinical data published by BrainStorm chief scientist Professor Daniel Offen of Tel Aviv University, the company says it will conduct additional studies using the Experimental Autoimmune Encephalomyelitis (EAE) animal model to evaluate MS as an additional indication for its NurOwn™ technology. NurOwn induces bone marrow-derived mesenchymal stem cells (MSC) to secrete high levels of neurotrophic factors…